Download PDF
Drug Res (Stuttg) 2016; 66(11): 580-586
DOI: 10.1055/s-0042-112811
Review
© Georg Thieme Verlag KG Stuttgart · New York

An Update on Biomedical Application of Nanotechnology for Alzheimer’s Disease Diagnosis and Therapy

Y. Panahi
1   Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
,
M. Mohammadhosseini
5   Department of Chemistry, Shahrood Branch, Islamic Azad University, Shahrood, Iran
,
A. J. N. Abadi
3   Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
,
A. Akbarzadeh
6   Stem Cell Research Center,Tabriz University of Medical Sciences, Tabriz, Iran
4   Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
,
H. Mellatyar
2   Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
4   Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
› Author Affiliations
Further Information

Publication History

received 07 July 2016

accepted 12 July 2016

Publication Date:
04 October 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Approximately 35 million people worldwide suffer from Alzheimer’s disease (AD). The cellular uptake and specific transport of drugs and imaging agents to brain are common issues in the diagnosis and therapy of AD. New advances in nanotechnology have supplied favorable solutions to this issue. Various nanocarriers such as polymeric nanoparticles, liposomes, micelles, dendrimers and nanogels have been studied for the delivery of drugs and imaging agents to brain. This review presents a succinct discussion of the applications of nanotechnology for Alzheimer’s disease diagnosis and therapy.

Key words

Alzheimer’s disease - blood-brain barrier (BBB) - nanotechnology
 

  • References

  • 1 Brambilla D, Le Droumaguet B, Nicolas J et al. Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomedicine: Nanotechnology, Biology, and Medicine 2011; 7: 521-540
    CrossrefPubMedGoogle Scholar
  • 2 Sahni JK, Doggui S, Ali J et al. Neurotherapeutic applications of nanoparticles in Alzheimer’s disease. Journal of Controlled Release 2011; 125: 208-231
    PubMedGoogle Scholar
  • 3 Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Annals of the New York Academy of Scinces 2010; 1184: 154-172
    PubMedGoogle Scholar
  • 4 Re R, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. Nanomedicine: Nanotechnology, Biology, and Medicine 2012; 8: 51-58
    CrossrefPubMedGoogle Scholar
  • 5 Pehlivan SB. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm Res 2013; 30: 2499-2511
    CrossrefPubMedGoogle Scholar
  • 6 Glat M, Skaat H, Menkes-Caspi N et al. Age-dependent effects of microglial inhibition in vivo on Alzheimer’s disease neuropathology using bioactive-conjugated iron oxide nanoparticles. Journal of Nanobiotechnology 2013; 11: 1-13
    CrossrefPubMedGoogle Scholar
  • 7 Cheng KK, Wang YX, Chow AHL et al. Amyloid plaques bindingcurcumin conjugated magneticnanoparticles for diagnosis in Alzheimer’s disease TG2576 mice. Neuropathology 2014; 1: 1-12
    PubMedGoogle Scholar
  • 8 Ansciaux E, Burtea C, Laurent S et al. In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood–brain barrier: toward earlier diagnosis of Alzheimer’s disease by molecular imaging. Contrast Media & Molecular Imaging 2015; 10: 211-224
    CrossrefPubMedGoogle Scholar
  • 9 Viola K, Sbarboro J, Sureka R et al. Towards non-invasive diagnostic imaging of early-stage Alzheimer’s disease. Nature Nanotechnology 2015; 10: 91-98
    PubMedGoogle Scholar
  • 10 Zhou J, Fa H, Yin W et al. Synthesis of superparamagnetic iron oxide nanoparticles coated with a DDNP-carboxyl derivative for in vitro magnetic resonance imaging of Alzheimer’s disease. Mater Sci Eng C Mater Biol Appl 2014; 1: 348-355
    PubMedGoogle Scholar
  • 11 Morris E, Chalkidou A, Hammers A et al. Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2016; 43: 374-385
    CrossrefPubMedGoogle Scholar
  • 12 Williame K, Chestera MJ, Yanming W. Thioflavin derivatives for use in the antemortem diagnosis of alzheimer’s disease and in vivo imaging and prevention of amyloid deposition. Patent Appl Publ within the TVPP – United States 2012;
    PubMedGoogle Scholar
  • 13 Escosura-Muñiz A, Plichta Z, Horák D et al. Alzheimer’s disease biomarkers detection in human samples by efficient capturing through porous magnetic microspheres and labelling with electrocatalytic gold nanoparticles. Biosensors and Bioelectronics 2015; 67: 162-169
    CrossrefPubMedGoogle Scholar
  • 14 Davoudi Z, Akbarzadeh A, Rahmatiyamchi M et al. Molecular target therapy of AKT and NF-kB signaling pathways and multidrug resistance by specific cell penetrating inhibitor peptides in HL-60 cells. Asian Pacific journal of cancer prevention: APJCP 15: 4353
    PubMedGoogle Scholar
  • 15 Lai L, Zhao Ch LiX et al. Fluorescent gold nanoclusters for in vivo target imaging of Alzheimer’s disease. RSC Adv 2016; 6: 30081-30088
    CrossrefPubMedGoogle Scholar
  • 16 Gregori M, Masserini M, Mancini S. Nanomedicine for the treatment of Alzheimer’s disease. Nanomedicine (Lond) 2015; 10: 1203-1218
    CrossrefPubMedGoogle Scholar
  • 17 Soursou G, Alexiou A, Ashraf GM et al. Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson ’s disease. Curr Drug Metab 2015; 16: 705-712
    CrossrefPubMedGoogle Scholar
  • 18 Jain KK. Nanobiotechnology-based strategies for crossing the blood–brain barrier. Nanomedicine 2012; 7: 1225-1233
    CrossrefPubMedGoogle Scholar
  • 19 Daraee H, Eatemadi A, Abbasi E et al. Application of gold nanoparticles in biomedical and drug delivery. Artificial cells, nanomedicine, and biotechnology 2014; 1-13
    PubMedGoogle Scholar
  • 20 Eatemadi A, Daraee H, Zarghami N et al. Nanofiber; synthesis and biomedical applications. Artificial cells, nanomedicine, and biotechnology. Artificial Cells, Nanomedicine, and Biotechnology 2014; 1-11
    PubMedGoogle Scholar
  • 21 Ahmad MZ, Ahmad J, Amin S et al. Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer’s disease. CNS Neurol Disord Drug Targets 2014; 13: 1315-1324
    CrossrefPubMedGoogle Scholar
  • 22 Arevalo MA, Azcoitia I, Garcia-Segura LM. The neuroprotective actions of oestradiol and oestrogen receptors. Nature Reviews Neuroscience 2015; 16: 17-29
    PubMedGoogle Scholar
  • 23 Hagl S, Heinrich M, Kocher A et al. Curcumin micelles improve mitochondrial function in a mouse model of Alzheimer’s disease. The Journal of Prevention of Alzheimer’s Disease 2014; 1: 80-83
    PubMedGoogle Scholar
  • 24 Mathew A, Fukuda T, Nagaoka Y et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS ONE 2012; 7: 1-10
    PubMedGoogle Scholar
  • 25 Cheng KK, Chan PS, Fan Sh et al. Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer’s disease mice using magnetic resonance imaging (MRI). Biomaterials 2015; 44: 155-172
    CrossrefPubMedGoogle Scholar
  • 26 Alimirzalu S, Akbarzadeh A, Abbasian M et al. Physicochemical characteristics of Fe3O4 magnetic nanocomposites based on poly(Nisopropylacrylamide) for anti-cancer drugs delivery. Asian Pac J Cancer Prev 2014; 15: 049-054
    CrossrefPubMedGoogle Scholar
  • 27 Cheng KK, Yeung SF, Ho ShW et al. Highly stabilized curcumin nanoparticles tested in an in vitro blood–brain barrier model and in Alzheimer’s disease Tg2576 mice. The AAPS Journal 2013; 15: 324-336
    CrossrefPubMedGoogle Scholar
  • 28 Aaseth J, Skaug MA, Cao Y et al. Chelation in metal intoxication – Principles and paradigms. Journal of Trace Elements in Medicine and Biology 2015; 31: 260-266
    CrossrefPubMedGoogle Scholar
  • 29 Liu G, Garrett MR, Men P et al. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochimica et Biophysica Acta 2005; 1741: 246-225
    CrossrefPubMedGoogle Scholar
  • 30 Roney C, Kulkarni P, Arora V et al. Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer’s disease. Journal of Controlled Release 2005; 108: 193-214
    CrossrefPubMedGoogle Scholar
  • 31 Patel T, Zhou J, Piepmeier JM et al. Polymeric nanoparticles for drug delivery to the central nervous system. Advanced Drug Delivery Reviews 2012; 64: 701-705
    CrossrefPubMedGoogle Scholar
  • 32 Wong H, Yu WuX, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Advanced Drug Delivery Reviews 2012; 64: 686-700
    CrossrefPubMedGoogle Scholar
  • 33 Shah L, Yadav S, Amiji M. Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv and Transl Res 2013; 3: 336-351
    CrossrefPubMedGoogle Scholar
  • 34 Mourtas S, Lazar AN, Markoutsa E et al. Multifunctional nanoliposomes with curcuminelipid derivative and brain targeting functionality with potential applications for Alzheimer disease. European Journal of Medicinal Chemistry 2014; 50: 175-183
    PubMedGoogle Scholar
  • 35 Ordóñez-Gutiérrez L, Re F, Bereczki E et al. Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-β levels in APP/PS1 transgenic mice. Nanomedicine: Nanotechnology, Biology and Medicine 2015; 11: 421-430
    CrossrefPubMedGoogle Scholar
  • 36 Mourtas S, Lazar AN, Markoutsa E et al. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. European Journal of Medicinal Chemistry 2014; 80: 175-183
    CrossrefPubMedGoogle Scholar
  • 37 Balducci C, Mancini S, Minniti S et al. Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer’s disease mouse models. The Journal of Neuroscience 2014; 34: 14022-14031
    CrossrefPubMedGoogle Scholar
  • 38 Davaran S, Entezami AA. Hydrophilic copolymers prepared from acrylic type derivatives of ibuprofen containing hydrolyzable thioester bond. European Polymer Journal 1998; 34: 187-192
    CrossrefPubMedGoogle Scholar
  • 39 Steele JW, Lachenmayer ML, Ju S et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer’s mouse model. Molecular Psychiatry 2013; 18: 889-897
    CrossrefPubMedGoogle Scholar
  • 40 Karnoosh-Yamchi J, Mobasseri M, Akbarzadeh A et al. Preparation of pH sensitive insulin-loaded Nano hydrogels and evaluation of insulin releasing in different pH conditions. Molecular Biology Reports. 2014; Molecular biology reports 41: 6705-6712
    CrossrefPubMedGoogle Scholar
  • 41 Molina M, Asadian-Birjand M, Balach J et al. Stimuli-responsive nanogel composites and their application in nanomedicine. Chem Soc Rev 2015; 44: 6161-6186
    CrossrefPubMedGoogle Scholar
  • 42 Karimi M, Eslami M, Sahandi-Zangabad P et al. pH-Sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Nanomedicine and Nanobiotechnology 2016;
    PubMedGoogle Scholar
  • 43 Georgia S, Athanasios A, Ghulam M et al. Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease. Current Drug Metabolism 2015; 16: 705-712
    CrossrefPubMedGoogle Scholar
  • 44 Davaran S, Alimirzalu S, Nejati-Koshki K et al. Physicochemical characteristics of Fe3O4 magnetic nanocomposites based on poly(N-isopropylacrylamide) for anti-cancer drug delivery. Asian Pac J Cancer Prev 2014; 15: 49-54
    CrossrefPubMedGoogle Scholar
  • 45 Kalaiarasi S, Arjun P, Nandhagopal S et al. Development of biocompatible nanogel for sustained drug release by overcoming the blood brain barrier in zebrafish model. Journal of Applied Biomedicine 2016; 14: 157-169
    CrossrefPubMedGoogle Scholar
  • 46 Haupt Ch, Fändrich M. Biotechnologically engineered protein binders for applications in amyloid diseases. Trends in Biotechnology 2014; 32: 513-520
    CrossrefPubMedGoogle Scholar
  • 47 Somani S, Dufès Ch. Applications of dendrimers for brain delivery and cancer therapy. Nanomedicine 2014; 9: 2403-2414
    CrossrefPubMedGoogle Scholar
  • 48 Neelov IM, Janaszewska A, Klajnert B et al. Molecular properties of lysine dendrimers and their interactions with Aβ-peptides and neuronal cells. Current Medicinal Chemistry 2013; 20: 134-143
    PubMedGoogle Scholar
  • 49 Kalomiraki M, Thermos K, Chaniotakis NA. Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine 2016; 11: 1-12
    CrossrefPubMedGoogle Scholar
  • 50 Nazem A, Mansoori GA. Nanotechnology building blocks for intervention with Alzheimer’s disease pathology: implications in disease modifying strategies. Journal of Bioanalysis & Biomedicine 2014; 6: 9-14
    CrossrefPubMedGoogle Scholar
  • 51 Eatemadi A, Daraee H, Zarghami N et al. Nanofiber; Synthesis and Biomedical Applications. Artificial Cells, Nanomedicine, and Biotechnology. 2014; : 1-11
    PubMedGoogle Scholar
  • 52 Mohammadzadeh G, Zarghami N. Associations between single- nucleotide polymorphisms of the adiponectin gene, serum adiponectin levels and increased risk of type 2 diabetes mellitus in Iranian obese individuals Scandinavian. Journal of Clinical and Laboratory Investigation 69 2009; 764-771
    PubMedGoogle Scholar